{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T01:26:13Z","timestamp":1771032373605,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1124\/jpet.112.195693","type":"journal-article","created":{"date-parts":[[2012,5,23]],"date-time":"2012-05-23T04:50:13Z","timestamp":1337748613000},"page":"576-585","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["L-745,870 Reduces l-DOPA-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease"],"prefix":"10.1016","volume":"342","author":[{"given":"Philippe","family":"Huot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom H.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James B.","family":"Koprich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Aman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.112.195693_bib1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.neuropharm.2009.08.010","article-title":"D4 and D1 dopamine receptors modulate [3H] GABA release in the substantia nigra pars reticulata of the rat","volume":"57","author":"Acosta-Garc\u00eda","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.112.195693_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.112.195693_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0006-8993(96)01422-9","article-title":"Cellular distribution of the rat D4 dopamine receptor protein in the CNS using anti-receptor antisera","volume":"752","author":"Ariano","year":"1997","journal-title":"Brain Res"},{"key":"10.1124\/jpet.112.195693_bib4","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.112.195693_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00702-003-0094-7","article-title":"Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile","volume":"111","author":"Bartoszyk","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1124\/jpet.112.195693_bib6","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-3565(24)37123-X","article-title":"L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests","volume":"283","author":"Bristow","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.195693_bib7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0165-6147(97)01066-3","article-title":"Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist","volume":"18","author":"Bristow","year":"1997","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.112.195693_bib8","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1021\/jm030505a","article-title":"Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction","volume":"47","author":"Cowart","year":"2004","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.112.195693_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","article-title":"Primate models of movement disorders of basal ganglia origin","volume":"13","author":"DeLong","year":"1990","journal-title":"Trends Neurosci"},{"key":"10.1124\/jpet.112.195693_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archneur.64.1.20","article-title":"Circuits and circuit disorders of the basal ganglia","volume":"64","author":"DeLong","year":"2007","journal-title":"Arch Neurol"},{"key":"10.1124\/jpet.112.195693_bib11","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.neuropharm.2008.08.031","article-title":"Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat","volume":"55","author":"Dupre","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.112.195693_bib12","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1007\/BF01485901","article-title":"[Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.]","volume":"38","author":"Ehringer","year":"1960","journal-title":"Klin Wochenschr"},{"key":"10.1124\/jpet.112.195693_bib13","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov Disord"},{"issue":"Suppl 3","key":"10.1124\/jpet.112.195693_bib14","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1002\/mds.22028","article-title":"The history of dopamine and levodopa in the treatment of Parkinson's disease","volume":"23","author":"Fahn","year":"2008","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.112.195693_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejphar.2004.07.078","article-title":"Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus","volume":"498","author":"Floran","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.112.195693_bib16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0306-4522(98)00633-2","article-title":"Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcriptase-polymerase chain reaction and autoradiography","volume":"91","author":"Flores","year":"1999","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.112.195693_bib17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mds.21897","article-title":"Placebo influences on dyskinesia in Parkinson's disease","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.112.195693_bib18","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1523\/JNEUROSCI.4223-07.2007","article-title":"RGS9\u20132 negatively modulates l-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease","volume":"27","author":"Gold","year":"2007","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.112.195693_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"l-Dopa in parkinsonian monkeys","volume":"15","author":"Gr\u00e9goire","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1124\/jpet.112.195693_bib20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.nbd.2007.02.001","article-title":"Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates","volume":"26","author":"Guigoni","year":"2007","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.112.195693_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-2999(00)00310-1","article-title":"Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys","volume":"399","author":"Hadj Tahar","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.112.195693_bib22","first-page":"387","article-title":"Zur pathologic der paralysis agitans und des postenzephalitischen parkinsonismus","volume":"48","author":"Hassler","year":"1938","journal-title":"J Psychol Neurol (Lpz)"},{"key":"10.1124\/jpet.112.195693_bib23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney Multicenter Study of Parkinson's disease: non-l-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.112.195693_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/jpet.112.195693_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","article-title":"The serotonergic system in Parkinson's disease","volume":"95","author":"Huot","year":"2011","journal-title":"Prog Neurobiol"},{"key":"10.1124\/jpet.112.195693_bib26","series-title":"Guide for the Care and Use of Laboratory Animals","year":"1996"},{"key":"10.1124\/jpet.112.195693_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/BF00241410","article-title":"Mapping of the colocalization of calretinin and tyrosine hydroxylase in the rat substantia nigra and ventral tegmental area","volume":"99","author":"Isaacs","year":"1994","journal-title":"Exp Brain Res"},{"key":"10.1124\/jpet.112.195693_bib28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"l-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/jpet.112.195693_bib29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"l-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.195693_bib30","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/mds.23172","article-title":"The \u03b12 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates","volume":"25","author":"Johnston","year":"2010","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.112.195693_bib31","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/mds.23069","article-title":"Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease","volume":"25","author":"Johnston","year":"2010","journal-title":"Mov Disord"},{"key":"10.1124\/jpet.112.195693_bib32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1136\/jnnp.37.4.427","article-title":"l-dopa induced dyskinesias","volume":"37","author":"Klawans","year":"1974","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/jpet.112.195693_bib33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/archpsyc.1997.01830180085011","article-title":"The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group","volume":"54","author":"Kramer","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/jpet.112.195693_bib34","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1021\/jm9600712","article-title":"3-[[4-(4-Chlorophenyl)piperazin-1-yl]-methyl]-1H-pyrrolo[2,3-b]pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor","volume":"39","author":"Kulagowski","year":"1996","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.112.195693_bib35","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0014-2999(94)00782-3","article-title":"Modulation of the clozapine structure increases its selectivity for the dopamine D4 receptor","volume":"273","author":"Li\u00e9geois","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.112.195693_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-008-1452-9","article-title":"Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats","volume":"204","author":"Marin","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.112.195693_bib37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1460-9568.1998.00056.x","article-title":"Development and characterization of antibodies directed against the mouse D4 dopamine receptor","volume":"10","author":"Mauger","year":"1998","journal-title":"Eur J Neurosci"},{"key":"10.1124\/jpet.112.195693_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: from structure to function","volume":"78","author":"Missale","year":"1998","journal-title":"Physiol Rev"},{"key":"10.1124\/jpet.112.195693_bib39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2005.02.004","article-title":"2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H-benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist","volume":"49","author":"Nakane","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.112.195693_bib40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","article-title":"Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)","volume":"27","author":"Olanow","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/jpet.112.195693_bib41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0301-0082(95)80010-6","article-title":"Chemical anatomy of primate basal ganglia","volume":"46","author":"Parent","year":"1995","journal-title":"Prog Neurobiol"},{"key":"10.1124\/jpet.112.195693_bib42","first-page":"111","article-title":"The dopaminergic nigropallidal projection in primates: distinct cellular origin and relative sparing in MPTP-treated monkeys","volume":"53","author":"Parent","year":"1990","journal-title":"Adv Neurol"},{"key":"10.1124\/jpet.112.195693_bib43","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0022-3565(24)37092-2","article-title":"Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor","volume":"283","author":"Patel","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.195693_bib44","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1468-1331.2005.01096.x","article-title":"Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study","volume":"12","author":"P\u00e9chevis","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1124\/jpet.112.195693_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/026988110201600301","article-title":"Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride","volume":"16","author":"Rabiner","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.112.195693_bib46","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1124\/jpet.112.195693_bib47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.0022-3042.2001.00702.x","article-title":"Dopamine D4 receptors are heterogeneously distributed in the striosomes\/matrix compartments of the striatum","volume":"80","author":"Rivera","year":"2002","journal-title":"J Neurochem"},{"key":"10.1124\/jpet.112.195693_bib48","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00018-010-0293-y","article-title":"The dopamine D4 receptor: biochemical and signalling properties","volume":"67","author":"Rondou","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"10.1124\/jpet.112.195693_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1096-9861(20000131)417:1<17::AID-CNE2>3.0.CO;2-I","article-title":"Single-axon tracing study of neurons of the external segment of the globus pallidus in primate","volume":"417","author":"Sato","year":"2000","journal-title":"J Comp Neurol"},{"key":"10.1124\/jpet.112.195693_bib50","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1021\/jm0305669","article-title":"Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning","volume":"47","author":"Stewart","year":"2004","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.112.195693_bib51","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0022-3565(24)36884-3","article-title":"I. NGD 94\u20131: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor","volume":"282","author":"Tallman","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.195693_bib52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.nbd.2008.11.010","article-title":"Dopamine D3 receptor stimulation underlies the development of l-DOPA-induced dyskinesia in animal models of Parkinson's disease","volume":"35","author":"Visanji","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.112.195693_bib53","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1124\/jpet.108.144097","article-title":"\u03b11-Adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques","volume":"328","author":"Visanji","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.195693_bib54","doi-asserted-by":"crossref","first-page":"22308","DOI":"10.1073\/pnas.1010025108","article-title":"Homeostatic regulation of glutamatergic transmission by dopamine D4 receptors","volume":"107","author":"Yuen","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/jpet.112.195693_bib55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0091-3057(01)00499-3","article-title":"Nigrostriatal dopaminergic denervation enhances dopamine D4 receptor binding in rat caudate-putamen","volume":"69","author":"Zhang","year":"2001","journal-title":"Pharmacol Biochem Behav"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524182791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524182791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.112.195693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T17:09:14Z","timestamp":1739984954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524182791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0022356524182791"],"URL":"https:\/\/doi.org\/10.1124\/jpet.112.195693","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L-745,870 Reduces l-DOPA-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.112.195693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}